Given these deleterious interactions of OBCs and CD4+ T cells, anti-CD4 mAb therapies may be interesting to prevent bone loss after allo-HCT in MPN patients (illustrated in Figure 1B). The gene discussed is CD4; the disease is myeloproliferative disorder.